MedTrace Logo

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

NCT00780910 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2026-01-06

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

MP-424

750 mg every 8 hours for 12 weeks

DRUG

Ribavirin

600 - 1000 mg/day based on body weight for 24 weeks

DRUG

Peginterferon Alfa-2b

1.5 mcg/kg/week for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Fumitaka Suzuki, MD · Department of Hepatology, Toranomon Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00780910 on ClinicalTrials.gov